Want to track 4ABBV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 84 days
Summary
4ABBV trading today higher at €169.6, an increase of 0.71% from yesterday's close, completing a monthly increase of 6.94% or €11. Over the past 12 months, 4ABBV stock lost -2.45%.
4ABBV pays dividends to its shareholders, with the most recent payment made on May 15, 2025. The next announced payment will be in In 1 weeks on Aug 15, 2025 for a total of €1.64.
The last earnings report, released on Jul 31, 2025, missed the consensus estimates by -2.89%. On average, the company has fell short of earnings expectations by -1.05%, based on the last three reports. The next scheduled earnings report is due on Oct 28, 2025.
The stock of the company had never split.
The company's stock is traded on 16 different exchanges and in various currencies, with the primary listing on NYSE (USD).
4ABBV Chart
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks | 41 minutes ago
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Zacks | 52 minutes ago
How Did Skyrizi and Rinvoq Sales Contribute to AbbVie's Q2 Results?
AbbVie's Q2 results show Skyrizi and Rinvoq powering growth, offsetting Humira declines and lifting 2025 sales outlook.
Zacks | 1 day ago
ABBVIE Dividends
 ABBV 3 weeks ago Announced | Quarterly | $1.64 Per Share |
| ABBV 3 months ago Paid | Quarterly | $1.64 Per Share |
| ABBV 6 months ago Paid | Quarterly | $1.64 Per Share |
| ABBV 9 months ago Paid | Quarterly | $1.55 Per Share |
| ABBV 15 Jul 2024 Paid | Quarterly | $1.55 Per Share |
ABBVIE Earnings
| 29 Oct 2025 (In 2 months) Date | | 3.27 Cons. EPS | - EPS |
| 28 Oct 2025 (In 2 months) Date | | 3.22 Cons. EPS | - EPS |
| 31 Jul 2025 Date | | 2.89 Cons. EPS | - EPS |
| 23 Jul 2025 Date | | 3.22 Cons. EPS | 2.97 EPS |
| 24 Apr 2025 Date | | - Cons. EPS | - EPS |
| ABBV 3 weeks ago Announced | Quarterly | $1.64 Per Share |
| ABBV 3 months ago Paid | Quarterly | $1.64 Per Share |
| ABBV 6 months ago Paid | Quarterly | $1.64 Per Share |
| ABBV 9 months ago Paid | Quarterly | $1.55 Per Share |
| ABBV 15 Jul 2024 Paid | Quarterly | $1.55 Per Share |
| 29 Oct 2025 (In 2 months) Date | | 3.27 Cons. EPS | - EPS |
| 28 Oct 2025 (In 2 months) Date | | 3.22 Cons. EPS | - EPS |
| 31 Jul 2025 Date | | 2.89 Cons. EPS | - EPS |
| 23 Jul 2025 Date | | 3.22 Cons. EPS | 2.97 EPS |
| 24 Apr 2025 Date | | - Cons. EPS | - EPS |
ABBVIE (4ABBV) FAQ
What is the stock price today?
The current price is €169.60.
On which exchange is it traded?
ABBVIE is listed on NYSE.
What is its stock symbol?
The ticker symbol is 4ABBV.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 6.2%.
What is its market cap?
As of today, no market cap data is available.
What is the earnings per share?
The EPS is 3.22.
When is the next earnings date?
The next earnings report will release on Oct 28, 2025.
Has ABBVIE ever had a stock split?
No, there has never been a stock split.
ABBVIE Profile
| Drug Manufacturers - General Industry | Healthcare Sector | Robert A. Michael CPA CEO | XMIL Exchange | US00287Y1091 ISIN |
| US Country | 55,000 Employees | 15 Jul 2025 Last Dividend | - Last Split | 2 Jan 2013 IPO Date |
Overview
AbbVie Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and sales of a wide range of pharmaceutical products. Incorporated in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing some of the world's most complex and critical health issues through its innovative medicines and therapies. In addition to its stand-alone operations, the company collaborates with several other leading institutions, including Calico Life Sciences LLC, REGENXBIO Inc., Janssen Biotech, Inc., Genentech, Inc., and Tentarix Biotherapeutics, LP. These collaborations aim to enhance AbbVie's research and development capabilities, particularly in the areas of oncology and immunology.
Products and Services
- Humira: A therapeutic injection for various autoimmune diseases, including intestinal Behçet's disease and pyoderma gangrenosum.
- Skyrizi: Prescribed for patients with moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease, focusing on improving skin health.
- Rinvoq: Targets multiple conditions such as rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, and several gastrointestinal diseases.
- Imbruvica: An oral medication for adults with various blood cancers, marking significant advancements in oncology.
- Epkinly and Elahere: Treatments tailored for different forms of lymphoma and cancer, showcasing AbbVie's innovations in targeted therapies.
- Venclexta/Venclyxto: Offers hope for patients battling blood cancers, through a regimen that interferes with cancer cell survival.
- Aesthetic Products: A range of facial injectables, plastics and regenerative medicine, body contouring, and skincare offerings that cater to aesthetic needs.
- Botox Therapeutic: Beyond cosmetic applications, this product is utilized for various therapeutic purposes, enhancing patient care.
- Vraylar: A medication designed to address depressive disorder, contributing to mental health treatment options.
- Duopa and Duodopa: These formulations provide relief for patients with advanced Parkinson's disease, improving quality of life.
- Ubrelvy and Qulipta: Target the acute treatment of migraine in adults, including both episodic and chronic forms.
- Ozurdex: An ocular implant designed to treat eye diseases, emphasizing AbbVie's contribution to ophthalmology.
- Lumigan/Ganfort and Alphagan/Combigan: Aimed at reducing intraocular pressure in conditions like open-angle glaucoma or ocular hypertension.
- Restasis: Helps increase tear production, addressing the needs of patients with dry eye disease.
- Mavyret/Maviret: Administered for the treatment of chronic hepatitis C virus (HCV) infection, representing a breakthrough in HCV treatment.
- Creon: A pancreatic enzyme therapy essential for patients with pancreatic insufficiency, aiding digestion.
- Lupron: Utilized for treating advanced prostate cancer, endometriosis, central precocious puberty, and uterine fibroids-related anemia.
- Linzess/Constella: Offers relief for irritable bowel syndrome with constipation and chronic idiopathic constipation.
- Synthroid: A synthetic thyroid hormone used to treat hypothyroidism, ensuring thyroid hormone levels are balanced.
Contact Information
Address: 1 North Waukegan Road
Phone: 847 932 7900
Website: https://www.abbvie.com
2025 © Marketlog. All Rights Reserved.
